

Medicines Optimisation Section 2022/23 – Overprescribing Webinar

Medicines and Prescribing Network
1 November 2022

LPCIS - Medicines Optimisation

LAMBETH MEDICINES OPTIMISATION SECTION (MOS): 01 April 2022 to 31 March 2023

The MOS will run from 1st April 2022 to 31st March 2023. Total funds available for the MOS is £350,000. All payments to be made at practice level.

TABLE 1


Priority Area	Measure	Monitoring Date	Payment Weighting per area
A. Respiratory	(i) $\geq 50\%$ of patients on tiotropium soft mist inhalers (Spiriva Respimat®, Spiolto Respimat®) of all patients prescribed tiotropium inhalers AND (ii) $\geq 80\%$ of patients on a triple combination inhaler of all patients who are using LAMA, LABA and ICS inhalers in the previous 3 months *Prescribers should recommend low carbon inhalers (soft mist, dry powder) when discussing treatment options with patients (in line with Investment and Impact Fund), although pressurised metered dose inhalers (with a spacer device) should be considered where there is insufficient inspiratory effort.	Monitoring of all comparators in 'January 2023 to March 2023 (Q4 2022-23)	20%
B. Self-Care	(i) $\leq 7.89\%$ of patients (of practice list size) on total self-care products AND TWO from (ii), (iii), (iv) and (v): (ii) $\leq 3.06\%$ of patients (of practice list size) on Vitamins and Minerals (iii) $\leq 0.80\%$ of patients (of practice list size) on Mild Dry Skin and Sunburn Products (iv) $\leq 0.90\%$ of patients (of practice list size) on Dry Eyes & Sore Tired Eye Products (v) $\leq 0.90\%$ of patients (of practice list size) on Mild to Moderate Hayfever and Seasonal Rhinitis drugs	Monitoring of all comparators in 'January 2023 to March 2023 (Q4 2022-23)	30%
C. Medicines Optimisation (via EZ Analytics Dashboard)	(i) $\leq 0.27\%$ of patients (of practice list size) on NHSE/I Low Priority Prescribing medicines AND (ii) $\leq 0.55\%$ of patients (of practice list size) on specials OR $\geq 10\%$ reduction of patients on specials spend* in Q4 2021-22 compared to Q4 2022-23 AND TWO from (iii), (iv), (v) (iii) $\leq 0.03\%$ of patients (of practice list size) on Lidocaine 5% plasters (iv) 0% of patients (of practice list size) on SEL IMOC Grey List medicines (medicines which are not recommended for routine prescribing) OR $\geq 50\%$ reduction in spend on SEL IMOC Grey List medicines in Q4 2021-22 compared to Q4 2022-23. (v) 90% of patients on a BGTS with Type 2 Diabetes to be on less than £9 per 50 strips AND 100% of patients on insulin are prescribed their insulin by brand	Monitoring of all comparators in 'January 2023 to March 2023 (Q4 2022-23)	20%
D. Overprescribing - Prescribing Processes & Medicines Safety	a) Overprescribing - reduce overprescribing to make patient care better and safer, support the NHS	Overprescribing Checklist completed and submitted by 31 March 2023	30%

*Data for these measures will be captured through EMIS Web-EZ Analytics

*Data for this measure will be captured through NHSBSA EPACT2

Cost per APU across Lambeth (Q4 2021/22)

--- Lambeth average cost per APU - £7.27



Overprescribing Checklist by 31 March 2023

a. Overprescribing & Medicines Safety		
Action	Yes/ No	Comments e.g. outcomes
<p>A shared action plan between the practice, PCN and the PCN lead/ local community pharmacist around developing safe and efficient processes in which the following is discussed, agreed and implemented for:</p> <ul style="list-style-type: none"> (i) ensuring timely, patient-centred structured medication reviews for those at high risk of overprescribing e.g. the frail elderly on polypharmacy, those with chronic pain, patients on the diabetes or hypertension or Severe Mental Illness (SMI) registers (ii) reducing inequalities for people more at risk of the consequences of overprescribing e.g. black, Asian, minority ethnic communities, those living in areas of high deprivation, those who are more vulnerable, such as the elderly and those with disabilities (iii) ensuring patients have been allowed time to consider what questions to ask about their medicines before shared decision making takes place (iv) ensuring deprescribing is incorporated when reviewing medicines e.g. reducing prescribing of dependency forming medicines such as opioids in pain management (v) ensuring robust systems are in place for monitoring patients prescribed for example: ACE inhibitors/ ARBs, loop diuretics, methotrexate, lithium, amiodarone and sodium valproate (in accordance to their respective requirements) (vi) minimising medication harm for these patients (vii) reporting and learning from prescribing/ medicines incidents <p>Developing a best practice process to incorporate (i) to (vii) above can support implementation, shared learning and improvement.</p>		
<p>Practice / PCN pharmacists attend Medicines and Prescribing Network meetings relating to overprescribing to support:</p> <ul style="list-style-type: none"> - personal development and clinical supervision, - delivering the goals set in the shared action plan, - to share key learning points within the PCN 		

b. Prescribing Processes		
Action	Yes/ No	Comments e.g. outcomes
<p>A shared action plan between the practice, PCN and the PCN lead/ local community pharmacist around medicines optimisation was discussed, agreed and implemented for:</p> <ul style="list-style-type: none"> (i) improving practice repeat prescribing processes? (ii) improving practice uptake and management of electronic Repeat Dispensing (eRD) after attending the 2022 SEL eRD webinar? 		
<p>The practice pharmacist actively reviews monthly Optimise Rx reports i.e. patients on 'Grey List,' 'Low Priority Prescribing medicines', 'Red List' medicines, Adult Oral Nutritional Supplements, Cow's Milk Allergy Products and in turn discusses findings at relevant practice meetings. Focus to be on priority areas, particularly those that have not been accepted.</p>		
<p>The practice pharmacist has shared key learning points e.g. within PCN and PCN pharmacist network</p>		

For post payment verification purposes, practice action plans for (a) Overprescribing & Medicines Safety, (b) Prescribing Processes may be required to be submitted

- EZ Analytics
 - Tracking progress
 - Identifying patients
 - Benchmarking against other practices
- EMIS searches - how to find patients who may be eligible for our scheme initiatives

Miscellaneous

- Antibiotics Stewardship
- eRD – 45.1%
- [SEL pharmacies](#) providing NHS Community Pharmacy BP Check Service
- Potential Generic Savings (Oct –Dec 21)

RESOURCES

- NHS SEL CCG website for MOS & LTC resources and checklists/ submissions: <https://selondonccg.nhs.uk/healthcare-professionals/primary-care/lambeth/lambeth-primary-care-improvement-scheme-2022-23/>
 - Webinar sessions e.g. DOAC webinars https://selondonccg.nhs.uk/covid_19/medications/
 - SEL IMOC documents e.g. SCG, position statements:
 - <https://selondonccg.nhs.uk/what-we-do/medicines-optimisation/south-east-london-integrated-medicines-optimisation-committee-sel-imoc/>
 - Lambeth Medicines Optimisation including policies on self-care: <https://selondonccg.nhs.uk/in-your-area/lambeth/medicines-optimisation/policies/>
- SEL Joint Formulary at: <https://www.selondonjointmedicinesformulary.nhs.uk/>
- Services available
 - Prescribing Support Dietetic Service Flyer
 - **Rapid Access Clinic referral form via DXS** under ‘Nutrition and Dietetics/Referral’
 - Email: gst-tr.prescribingsupportdietitians@nhs.net
 - Learning Disability and Autism team - selicb.ladaprescribingteam@nhs.net
 - Integrated Care Pharmacy Service (GSTT-Lambeth)
 - DXS: search ‘GSTT Integrated Pharmacy Lambeth’
 - Email: gst-tr.ICPPharmacyLambeth@nhs.net
 - Paediatric Specials Pharmacists Service
 - Helen.Cooper@gstt.nhs.uk
 - GSTT Medicines Information Service
 - medicinesinformation@gstt.nhs.uk
 - Medicines Complete - an online resource for drug and healthcare information
 - <https://about.medicinescomplete.com/> [see Bulletin for username & password for access]
- Medicines Optimisation Section 2022/23 document – details the reasons for inclusion in the MOS, explains further the metrics, signposts to resources and contains useful references
- NHS SEL CCG Quality Alert system
https://selccg.gateway.prod-uk.datixcloudiq.co.uk/capture/?form_id=2&module=